Related references
Note: Only part of the references are listed.Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension
Astrid Weiss et al.
NATURE COMMUNICATIONS (2019)
Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma
Jing Zhang et al.
MOLECULAR CANCER (2019)
CD146-HIF-1α hypoxic reprogramming drives vascular remodeling and pulmonary arterial hypertension
Yongting Luo et al.
NATURE COMMUNICATIONS (2019)
Smooth Muscle Contact Drives Endothelial Regeneration by BMPR2-Notch1-Mediated Metabolic and Epigenetic Changes
Kazuya Miyagawa et al.
CIRCULATION RESEARCH (2019)
Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma
Hangzhan Ma et al.
EBIOMEDICINE (2019)
CDK9: a signaling hub for transcriptional control
Curtis W. Bacon et al.
TRANSCRIPTION-AUSTIN (2019)
CDK9: A key player in cancer and other diseases
Lia Carolina Franco et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
MicroRNA-613 inhibits the progression of gastric cancer by targeting CDK9
Yebin Lu et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2018)
Therapeutic Targeting of Vascular Remodeling and Right Heart Failure in Pulmonary Arterial Hypertension with a HIF-2 alpha Inhibitor
Zhiyu Dai et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
PPARγ Regulates Mitochondrial Structure and Function and Human Pulmonary Artery Smooth Muscle Cell Proliferation
Samantha M. Yeligar et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2018)
Pulmonary arterial hypertension: pathogenesis and clinical management
Thenappan Thenappan et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Pulmonary arterial hypertension: pathogenesis and clinical management
Thenappan Thenappan et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer
Hanghang Zhang et al.
CELL (2018)
Exosomal 15-LO2 mediates hypoxia-induced pulmonary artery hypertension in vivo and in vitro
Min Zhang et al.
CELL DEATH & DISEASE (2018)
Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo
Liang Zhou et al.
BRITISH JOURNAL OF CANCER (2018)
Vascular peroxidase 1 mediates hypoxia-induced pulmonary artery smooth muscle cell proliferation, apoptosis resistance and migration
Baiyang You et al.
CARDIOVASCULAR RESEARCH (2018)
The emerging picture of CDK9/P-TEFb: more than 20 years of advances since PITALRE
Nikolas Ferreira dos Santos Paparidis et al.
MOLECULAR BIOSYSTEMS (2017)
The cancer theory of pulmonary arterial hypertension
Olivier Boucherat et al.
PULMONARY CIRCULATION (2017)
Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer
Ulrich Luecking et al.
CHEMMEDCHEM (2017)
Pyruvate Kinase and Warburg Metabolism in Pulmonary Arterial Hypertension Uncoupled Glycolysis and the Cancer-Like Phenotype of Pulmonary Arterial Hypertension
Stephen L. Archer
CIRCULATION (2017)
From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics Targeting Cell Growth and Proliferation Signaling Hubs
Soni Savai Pullamsettit et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)
Stress from Nucleotide Depletion Activates the Transcriptional Regulator HEXIM1 to Suppress Melanoma
Justin L. Tan et al.
MOLECULAR CELL (2016)
A global view of pulmonary hypertension
Marius M. Hoeper et al.
LANCET RESPIRATORY MEDICINE (2016)
Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1
J. Lemke et al.
CELL DEATH AND DIFFERENTIATION (2014)
CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma
Chun-Hao Huang et al.
GENES & DEVELOPMENT (2014)
LARP7 suppresses P-TEFb activity to inhibit breast cancer progression and metastasis
Xiaodan Ji et al.
ELIFE (2014)
A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
Jia Ji et al.
CLINICAL CANCER RESEARCH (2013)
Cdks, cyclins and CKIs: roles beyond cell cycle regulation
Shuhui Lim et al.
DEVELOPMENT (2013)
Inhibition of metastasis by HEXIM1 through effects on cell invasion and angiogenesis
W. Ketchart et al.
ONCOGENE (2013)
The monocrotaline model of pulmonary hypertension in perspective
Jose G. Gomez-Arroyo et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2012)
Cyclin T1 overexpression induces malignant transformation and tumor growth
Cristian Moiola et al.
CELL CYCLE (2010)
Flavopiridol, the First Cyclin-Dependent Kinase Inhibitor: Recent Advances in Combination Chemotherapy
L. -M. Wang et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2010)
Interleukin-6 Overexpression Induces Pulmonary Hypertension
M. Kathryn Steiner et al.
CIRCULATION RESEARCH (2009)
Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension
MS McMurtry et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP
EH Kim et al.
ONCOGENE (2004)
Binding of the 7SK snRNA turns the HEXIM1 protein into a P-TEFb (CDK9/cyclin T) inhibitor
AA Michels et al.
EMBO JOURNAL (2004)
Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy
M Sano et al.
NATURE MEDICINE (2002)
c-Myc mediates activation of the cad promoter via a post-RNA polymerase II recruitment mechanism
SR Eberhardy et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Flavopiridol inhibits P-TEFb and blocks HIV-1 replication
SH Chao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
